BCL2 and acute myeloid leukemia: Ongoing research through BCL2 gene characterization will provide insights into the emergence of its variants and the mechanism of venetoclax resistance at initial treatment of the lack of response at relapse, as well as the basis of the hopeful development of novel treatment approaches in AML R/R patients receiving this agent [71,81,82,136].